- Rating
- 2
- Confidence
- 3
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
Instead of proposing a new hematology learning paradigm from scratch, it further makes a more complete and systematic connection between cell-level multi-task models such as Uni-Hema and case-level aggregation models such as CAREMIL. It is valuable in that it tries to preserve explicit information such as cell category, morphology, composition and context before case aggregation, rather than just passing a plain embedding.
Critical strengths
-
The system provides relatively complete integration across tasks and scales. The main strength of Cell2Case is not a single new module, but that it brings several previously separate capabilities into one framework.
-
The patient-level representation does not rely only on black-box pooling. Hematologic diagnosis may depend not only on a few highly abnormal cells, but also on cell-type proportions and patterns across multiple views. Therefore, the way Cell2Case organizes patient-level information is reasonably aligned with the nature of hematopathology.
-
The experimental evaluation is relatively comprehensive. The paper evaluates multiple cell-level, language, and patient-level tasks, and also provides several component ablations.
Critical weaknesses
-
The main novelty is more about system integration than a new modeling principle. Before Cell2Case, DinoBloom had already studied foundation representations for blood cells. Uni-Hema had already unified detection, classification, segmentation, morphology prediction, VQA, and MLM. CAREMIL had already used cell morphology, cell composition, and attention-based aggregation for case-level diagnosis. Cell2Case combines these directions in a more complete system, but it does not clearly introduce a new learning paradigm. Its novelty is therefore closer to system design and integration, which makes the methodological contribution somewhat weaker.
-
The model is not as fully unified as the title may suggest. Not all seven tasks use the same CBME evidence. Different tasks still have separate adapters, prediction heads, losses, and training stages, and many modules are frozen during training. Segmentation also requires an additional segmentation ontology ID provided by dataset metadata. Therefore, it may be more accurate to describe Cell2Case as a multi-task system that shares part of its visual and cellular representations, rather than a model in which all tasks are unified through one common cellular evidence representation.
-
The patient-level task has strong cohort–label confounding. The seven diagnosis classes are not fully shared across the three cohorts. JHU contains only PML–RARA and AML-unspecified, while C-NMC contains only Control and B-ALL. Several other classes, including NPM1, CBFB–MYH11, and RUNX1–RUNX1T1, mainly come from MLL. This means that cohort identity itself contains substantial information about the diagnosis. The source-only baseline reaches 41.18% accuracy, which directly shows this dependence. The source-adversarial loss reduces linearly recoverable cohort information, but a near-random source probe does not prove that the model no longer uses cohort-related shortcuts. Nonlinear source information, staining differences, scanner differences, and biological signals that are correlated with both cohort and diagnosis are still difficult to separate completely. Therefore, the reported 75.01% balanced accuracy is best interpreted as patient-disjoint classification within a mixture of three already seen cohorts, rather than evidence of generalization to an unseen cohort.
Questions for authors
see weakness